ALBANY, New York, February 6, 2012 /PRNewswire/ --
In the news release, "Global Osteoporosis Market is Expected to Attain a Market Size of USD 6.8 billion in 2015, China Osteoporosis Market Will be Worth USD 2.5 Billion in 2015" issued on 31 Jan 2012 11:30 GMT, by Transparency Market Research over PR Newswire, we are advised by a representative of the company that in the headline "Market Size of USD 6.8 billion" has been changed to "Market Size of USD 11.4 billion".
According to a new report published by Transparency Market Research (http://www.transparencymarketresearch.com) "Osteoporosis Drug Market- Global and China market analysis, size, trends and forecast (2010-2015)" Global Osteoporosis Market is estimated to be USD 7.3 billion in 2010 and expected to reach USD 11.4 billion in 2015 at a CAGR of 9.2% over the period 2010 to 2015. Bisphosphonate segment accounted for the largest share at 62.0% of weight management market in 2010. China Osteoporosis market will be worth USD 2.5 billion in 2015.
Browse full report at: http://www.transparencymarketresearch.com/osteoporosis-drug-market.html
In 2009, the Global Osteoporosis Drug Market was worth USD 6.8 billion, with Bisphosphonate class of drugs leading the market. In the overall Bisphosphonate, ibandronate (Bonviva/Boniva; Roche) and zoledronate (Aclasta/Zometa; Novartis) accounted healthy market share and showed an average sales growth rate of about of 20% in the past 2 years.
Amgen's Denosumab is the recent entrant to the Osteoporosis treatment market, following its approval from the U.S. and European Union (also approved for bone loss associated with prostate cancer). Denosumab is expected to compete directly with the Bisphosphonate drug class. However, initial uptake of Denosumab is likely to be as second-line therapy, mostly in patients who are intolerant to Bisphosphonate. In addition to the treatment of Osteoporosis, there is substantial potential for Denosumab for treating bone loss in patients with cancer. Denosumab market is expected to reach USD 3.8 billion in 2015.
Our research indicates that the Osteoporosis drug pipeline is going strong with various phases of clinical development. Phase III has first-in-class products such as odanacatib, which possess a novel mechanism of action to combat Osteoporosis. Aprela is another drug in the stage of development.
The Chinese Osteoporosis drug market is expected to grow at a CAGR of 13.5% from 2010 to 2015. Increased prevalence of Osteoporosis among Chinese female population is the principal growth driver of the Osteoporosis drug market. The other key growth drivers for Chinese Osteoporosis market include increasing elderly aged population, rising living standards of the Chinese people and increasing awareness and bone health education.
To gain a competitive advantage, market players should develop cost-competitive drugs with easy dosage pattern, which promote bone building effectively. Large numbers of patients are unable to comply with the strict dosage schedule of traditional Osteoporosis drugs. Further research and development can address the unmet need by coming up with drugs that have a convenient dosage schedule with better efficacy and safety compared to traditional treatment of Osteoporosis.
This report provides in-depth analysis of global and China Osteoporosis Market based on following segmentation:
Related & Recently Published Reports by Transparency Market Research
Browse all Pharmaceutical Market Research Reports
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
90 Sate Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453
|SOURCE Transparency Market Research|
Copyright©2010 PR Newswire.
All rights reserved